ProCE Banner Activity

Advantages of and Barriers to Patient Participation in IBD Clinical Trials

Clinical Thought
Clinical trials provide great opportunities for individual patients and the IBD community as a whole, but several barriers prevent optimal recruitment.

Released: August 17, 2021

Expiration: August 16, 2022

Share

Faculty

Millie D. Long

Millie D. Long, MD, MPH, FACG, AGAF

Professor of Medicine
Director,
Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Millie D. Long, MD, MPH, FACG, AGAF

Professor of Medicine
Director,
Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Millie D. Long, MD, MPH, has disclosed that she has received consulting fees from AbbVie, Gilead Sciences, Janssen, Pfizer, Prometheus, Salix, Takeda, Target PharmaSolutions, UCB, and Valeant and funds for research support from Pfizer and Takeda.